Charité Center for Internal Medicine and Dermatology, Division for General Internal and Psychosomatic Medicine, Charité- Universitätsmedizin Berlin, Berlin, Germany.
Obes Rev. 2013 Nov;14(11):859-70. doi: 10.1111/obr.12063. Epub 2013 Aug 27.
Nesfatin-1 was discovered in 2006 and introduced as a potential novel anorexigenic modulator of food intake and body weight. The past years have witnessed increasing evidence establishing nesfatin-1 as a potent physiological inhibitor of food intake and body weight and unravelled nesfatin-1's interaction with other brain transmitters to exert its food consumption inhibitory effect. As observed for other anorexigenic brain neuropeptides, nesfatin-1 is also likely to exert additional, if not pleiotropic, actions in the brain and periphery. Recent studies established the prominent expression of the nesfatin-1 precursor, nucleobindin2 (NUCB2), in the stomach and pancreas, where nesfatin-1 influences endocrine secretion. This review will highlight the current experimental state-of-knowledge on the effects of NUCB2/nesfatin-1 on food intake, body weight and glucose homeostasis. Potential implications in human obesity will be discussed in relation to the evidence of changes in circulating levels of NUCB2/nesfatin-1 in disease states, the occurrence of genetic NUCB2 polymorphisms and--in contrast to several other hormones--the independence of leptin signalling known to be blunted under conditions of chronically increased body weight.
Nesfatin-1 于 2006 年被发现,并被认为是一种潜在的新型厌食性食物摄入和体重调节因子。过去几年的研究证据越来越多,证明 nesfatin-1 是一种强大的生理性食物摄入和体重抑制因子,并揭示了 nesfatin-1 与其他脑递质的相互作用,以发挥其抑制食物消耗的作用。与其他厌食性脑神经肽一样,nesfatin-1 也可能在大脑和外周组织中发挥额外的作用,如果不是多效性的作用。最近的研究确定了 nesfatin-1 前体核结合蛋白 2(NUCB2)在胃和胰腺中的显著表达,nesfatin-1 影响内分泌分泌。这篇综述将重点介绍目前关于 NUCB2/nesfatin-1 对食物摄入、体重和葡萄糖稳态的影响的实验研究现状。将讨论其在人类肥胖中的潜在意义,同时考虑到疾病状态下循环 NUCB2/nesfatin-1 水平变化的证据、NUCB2 遗传多态性的发生,以及与其他几种激素不同的是,瘦素信号的独立性,已知在慢性体重增加的情况下会受到抑制。